Level of Melanotransferrin in Tissue and Sera Serves as a Prognostic Marker of Gastric Cancer.
Adenocarcinoma
/ blood
Adult
Aged
Aged, 80 and over
Apoptosis
Biomarkers, Tumor
/ blood
Case-Control Studies
Cell Proliferation
Female
Follow-Up Studies
Gene Expression Regulation, Neoplastic
Humans
Male
Membrane Glycoproteins
/ blood
Middle Aged
Neoplasm Recurrence, Local
/ blood
Prognosis
Stomach Neoplasms
/ blood
Tumor Cells, Cultured
Gastric cancer
biomarker
melanotransferrin
Journal
Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988
Informations de publication
Date de publication:
Nov 2019
Nov 2019
Historique:
received:
09
10
2019
revised:
21
10
2019
accepted:
22
10
2019
entrez:
10
11
2019
pubmed:
11
11
2019
medline:
26
11
2019
Statut:
ppublish
Résumé
The aim of the study was to identify novel biomarkers that are vital for improving management of patients with gastric cancer (GC). An RNA-sequencing analysis was conducted using gastric tissue from patients with metastatic GC. In vitro cell functions were evaluated by siRNA-mediated knockdown assays. A total of 230 pairs of gastric tissue were subjected to expression analysis of mRNA and protein in situ. The serum levels of the candidate biomarker were determined by ELISA. MELTF was identified as a candidate biomarker. Inhibition of MELTF expression suppressed the invasion ability of GC cells. Increased tissue MELTF mRNA expression was associated with shorter survival. Furthermore, staining intensity of tissue MELTF protein was linked to recurrence rates. Serum MELTF levels gradually were increased from healthy controls to advanced GC. Patients with high serum MELTF levels had poor prognosis. Both tissue and serum MELTF levels may serve as biomarkers of GC progression.
Identifiants
pubmed: 31704840
pii: 39/11/6125
doi: 10.21873/anticanres.13820
doi:
Substances chimiques
Biomarkers, Tumor
0
MELTF protein, human
0
Membrane Glycoproteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
6125-6133Informations de copyright
Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.